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A B S T R A C T
Chinese hamster ovary (CHO) cell expression systems have been exquisitely developed for the production of
recombinant biotherapeutics (e.g. standard monoclonal antibodies, mAbs) and are able to generate eﬃcacious,
multi-domain proteins with human-like post translational modiﬁcations at high concentration with appropriate
product quality attributes. However, there remains a need for development of new CHO cell expression systems
able to produce more challenging secretory recombinant biotherapeutics at higher yield with improved product
quality attributes. Amazingly, the engineering of lipid metabolism to enhance such properties has not been
investigated even though the biosynthesis of recombinant proteins is at least partially controlled by cellular
processes that are highly dependent on lipid metabolism. Here we show that the global transcriptional activator
of genes involved in lipid biosynthesis, sterol regulatory element binding factor 1 (SREBF1), and stearoyl CoA
desaturase 1 (SCD1), an enzyme which catalyzes the conversion of saturated fatty acids into monounsaturated
fatty acids, can be overexpressed in CHO cells to diﬀerent degrees. The amount of overexpression obtained of
each of these lipid metabolism modifying (LMM) genes was related to the subsequent phenotypes observed.
Expression of a number of model secretory biopharmaceuticals was enhanced between 1.5-9 fold in either
SREBF1 or SCD1 engineered CHO host cells as assessed under batch and fed-batch culture. The SCD1 over-
expressing polyclonal pool consistently showed increased concentration of a range of products. For the SREBF1
engineered cells, the level of SREBF1 expression that gave the greatest enhancement in yield was dependent
upon the model protein tested. Overexpression of both SCD1 and SREBF1 modiﬁed the lipid proﬁle of CHO cells
and the cellular structure. Mechanistically, overexpression of SCD1 and SREBF1 resulted in an expanded en-
doplasmic reticulum (ER) that was dependent upon the level of LMM overexpression. We conclude that ma-
nipulation of lipid metabolism in CHO cells via genetic engineering is an exciting new approach to enhance the
ability of CHO cells to produce a range of diﬀerent types of secretory recombinant protein products via mod-
ulation of the cellular lipid proﬁle and expansion of the ER.
1. Introduction
Chinese hamster ovary (CHO) cells are routinely employed for the
production of recombinant biotherapeutics such as monoclonal anti-
bodies (mAbs) (Walsh, 2018; Feary et al., 2017; Mead et al., 2015;
Povey et al., 2014). Their endogenous cellular machinery facilitates
eﬃcient protein folding and human-like post-translational modiﬁcation
of complex multi-domain, multi-chain molecules and the generation of
eﬃcacious therapeutic material. Furthermore, their ability to grow in
suspension culture in chemically deﬁned, animal component free media
has made them an attractive host for the production of such molecules
and CHO cells are now the most commonly employed host for gen-
eration of recombinant biotherapeutics. Advances in high throughput
technology, cell culture and cell line development processes including
vector, expression host and media improvements focused upon ex-
panding transcriptional capacity, sugar/amino acid/chaperone meta-
bolism and manipulation, and avoiding lactate accumulation have en-
abled manufacturers to regularly achieve concentrations> 5 g/L of
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mAb (Marichal-Gallardo and Álvarez, 2012).
Although CHO cell platforms for standard format mAb production
are well reﬁned, the emergence of new, novel format biotherapeutic
molecules that are often non-natural has presented new challenges for
existing CHO cell hosts rendering such proteins ‘diﬃcult to express’
(DTE). Despite this, the current approach used by industry to create cell
lines expressing the desired DTE protein is to force a ‘ﬁt’ with the
systems and processes successfully used with mAbs (Laux et al., 2013).
These existing host cell lines have not evolved pathways for eﬃcient
synthesis, folding, assembly and secretion of DTE next-generation bio-
logics (NGBs) of appropriate quality, resulting in signiﬁcantly reduced
growth and low productivity and product quality (Johari et al., 2015).
There is thus a need to develop systems for improved productivity and
reduced product quality issues with DTE proteins. Eﬀorts to date have
been based around media and process development through high
throughput screening applied to current expression platforms (Pybus
et al., 2014) and the use of medium additives (e.g. DMSO), host cell line
engineering; and modifying expression vector architecture. Others have
approached the problem via the manipulation of (a) the unfolded
protein response and endoplasmic reticulum (ER) associated chaper-
ones, foldases and protein degradation (Johari et al., 2015; Pybus et al.,
2014), (b) via secretion and manipulation of soluble N-ethylmaleimide-
sensitive factor attachment protein receptors (SNAREs) and compo-
nents of the translational machinery (Le Fourn et al., 2014) or (c) en-
gineering of the target protein itself (protein engineering) (Grote et al.,
2012).
Although there have been attempts to manipulate multiple aspects
of CHO cell biology to improve their ability to grow and/or synthesize
and secrete recombinant biotherapeutics, one area which has received
little attention to date is that of lipid biosynthesis. Lipids are the major
component of cellular membranes, and are integral in a kaleidoscope of
essential cellular activities such as energy metabolism, cell signaling,
cell growth and survival, organelle formation and containment, and
transport/secretion via vesicle formation and traﬃcking (Marichal-
Gallardo and Álvarez, 2012). It is therefore surprising that lipid meta-
bolism has been little studied in a CHO cell bioprocessing context. One
of the few studies in this area compared lipid proﬁles of CHO, HEK293
and SP2/0-Ag14 cells and concluded that a knowledge of lipid meta-
bolism could help deﬁne physiological diﬀerences across diﬀerent
mammalian recombinant protein production hosts and help guide me-
tabolic engineering and medium formulation to improve production of
biotherapeutics (Zhang et al., 2017).
Glycerophospholipids are the most abundant lipid species in eu-
karyotic cells and consist of phosphatidylcholine (PC), phosphatidy-
lethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA)
and phosphatidylinositol (PI). Whilst PC is the most abundant lipid
species in a mammalian cell, varying ratios of lipid species, in combi-
nation with incorporation of diﬀerent membrane proteins, inﬂuences
membrane and cellular properties (van Meer et al., 2008). For example,
the ER requires a speciﬁc membrane ﬂuidity as it is the primary se-
cretory organelle for traﬃcking of proteins and lipids whilst the plasma
membrane requires a more rigid membrane to provide cellular structure
(Monje-Galvan and Klauda, 2015; Jackson et al., 2016). The ER is not
only the primary site of de novo lipid biogenesis but also the initial
organelle involved in vesicle traﬃcking in the exocytic pathway by
which proteins are transported to the Golgi and eventually secreted
from the cell. The ER is typically a large organelle contained by a
continuous membrane system and lipid turnover in the ER is crucial for
optimal ER and, in turn, cellular function. Overall, cellular lipid
homeostasis is governed by a balance of de novo biogenesis and mem-
brane traﬃcking together with the modiﬁcation of existing lipid species
subsequent to their synthesis. These homeostatic pathways can be ac-
tivated or suppressed in response to speciﬁc cellular conditions such as
temperature, redox status and cellular sterol levels (Han and Kaufman,
2016). For example, the unfolded protein response (UPR) can be in-
duced by the excessive accumulation of lipids intracellularly and results
in the regulation of ER quantity in the cell through synthesis of both
proteins and lipids (Han and Kaufman, 2016). X box binding protein 1
(XBP1) is a key regulator of the UPR and processing of XBP1 induces the
formation of a speciﬁc splice variant which upregulates a cascade of
genes including stearoyl CoA desaturase 1 (SCD1), diacylglycerol O-
acyltransferase 2 (DGAT2) and acetyl CoA carboxylase (ACC) which
serve to modify cellular lipid content. Overexpression of XBP1 has been
shown to expand the ER of CHO cells and has subsequently been suc-
cessfully employed to improve recombinant protein production yields
(Tigges and Fussenegger, 2006).
With regard to temperature stress and the homeostatics of lipid
biosynthesis, we, and others, have previously shown that at sub-
physiological temperatures (< 37 °C, particularly around 32 °C) cells
respond to such sub-optimal temperature by changing the abundance
and saturation level of a range of lipids, particularly increasing the level
of unsaturated fatty acids (Roobol et al., 2011). Under such culture
temperature conditions, secretory recombinant protein yields from
CHO cells can be increased (Masterton et al., 2010), and we therefore
set out to investigate (1) whether the engineering of CHO cells to ma-
nipulate the abundance and unsaturation of lipids would result in
changes to the amounts and saturation level of lipids in CHO cells and
(2) if this resulted in increased secretory recombinant protein yields,
particularly for diﬃcult to express proteins, at physiological tempera-
tures. To achieve this we targeted manipulation of genes/proteins di-
rectly involved in generating unsaturated lipids and/or that globally
control lipid biosynthesis in CHO cells via engineering of sterol
Abbreviations:
ACC acetyl CoA carboxylase
AMP adenosine monophosphate
AMPK adenosine monophosphate activated protein kinase
CAB sodium cacodylate
CHO Chinese hamster ovary
DGAT2 diacylglycerol O-Acyltransferase 2
DTE diﬃcult to express
FcFP Fc fusion protein
GS glutamine synthetase
INSIG insulin-induced gene 1
IVC integral of viable cells
LMM lipid metabolism modiﬁer
mAb monoclonal antibody
MSX methionine sulfoximine








SCAP SREBF cleavage-activating protein
SCD1 stearoyl CoA desaturase 1
SFA saturated fatty acid
SNAREs soluble N-ethylmaleimide-sensitive factor attachment
protein receptors
SRE sterol regulatory element
SREBF1 sterol regulatory element binding factor 1
TAG triacylglycerol
XBP1 X box binding protein 1
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regulatory element binding factor 1 (SREBF1) and SCD1.
SREBF1 is a global transcriptional regulator capable of activating a
plethora of genes involved in lipid metabolism including de novo lipo-
genesis, fatty acid re-esteriﬁcation, phospholipid biosynthesis and fatty
acid desaturation (Fig. 1). The activity of SREBF1 as a transcriptional
activator is governed by its post-translational processing in the cell.
Initially, SREBF1 localizes to the ER membrane where it integrates into
the phospholipid bilayer and forms a complex with SREBF cleavage-
activating protein (SCAP) which can facilitate migration of SREBF1 to
the Golgi. However, under high cellular sterol levels (particularly
cholesterol) a conformational change in SCAP is induced which aids
binding to the membrane integral protein insulin-induced gene 1
(INSIG), inhibiting migration of this complex from the ER. In the ab-
sence of sterols, INSIG does not bind to SCAP, allowing migration of the
SREBF:SCAP complex to the Golgi. Sequential proteolytic cleavage of
SREBF1 occurs in the Golgi mediated by site-1 protease (S1P) and site-2
protease (S2P) proteins liberating the N-terminal basic helix loop helix
leucine zipper (bHLHLz) in the cytosol. Lysine residues present on the
cleaved SREBF1 are ubiquitinated and degraded by the 26S protea-
some, but this ubiquitination can be inhibited through acetylation of
the lysine residues, which allows migration to the nucleus. Finally,
mature nuclear SREBF1 binds to sterol regulatory element (SRE) se-
quences upstream of various genes involved in lipid metabolism
causing them to be transcriptionally activated (Scaglia et al., 2009;
Shimano, 2001).
SCD1 expression is itself partially controlled by SREBF1 mediated
transcriptional activation, and is localized to the ER where it catalyzes
the conversion of saturated fatty acids (SFA) to monounsaturated fatty
acids (MUFA). An increase in the MUFA:SFA ratio results in greater
membrane ﬂuidity and cell signaling as well as the formation of tria-
cylglycerol (TAG) containing lipid droplets (Ren et al., 2018; Maulucci
et al., 2016; Jaureguiberry et al., 2014). SCD1 also controls the phos-
phorylation status of adenosine monophosphate (AMP) activated pro-
tein kinase (AMPK), consequentially reducing its ability to
phosphorylate and inhibit acetyl CoA carboxylase (ACC); a rate-limiting
enzyme in the lipid synthesis process. Finally, desaturation of SFA
prevents their accumulation, which can cause cell death through lipo-
toxicity. Together the aforementioned functions of SCD1 result in in-
creased lipid biosynthesis, cell survival and proliferation rates (Igal and
Ariel, 2011; Igal, 2016).
In this study we show that overexpression of SCD1 and SREBF1 in
the Lonza Biologics’ proprietary CHOK1SV GS-KO™ host cell line; a
glutamine synthetase (GS) knockout host cell line, results in enhanced
secreted recombinant protein yields of a number of diﬀerent model
biotherapeutic proteins, although this is dependent upon the amount of
overexpression of the lipid metabolism modifying (LMM) genes (SCD1
and SREBF1). Their overexpression also inﬂuenced cell growth and
batch culture longevity. Mass spectrometry based lipidomics analysis
conﬁrmed that genetic manipulation of lipid metabolism altered the
global lipid proﬁle of engineered cells whilst speciﬁc lipids were up or
down regulated compared to the host cell in the LMM engineered cells.
Electron microscopy imaging revealed substantial changes to the
structure and membranes of LMM engineered cells compared to con-
trols. Finally, LMM engineered cells were shown to have an expanded
ER compared to control cells that was related to the amount of LMM
overexpression and improvement in secretory biotherapeutic protein
production, suggesting that expansion of the ER may at least partially
underpin the enhanced secretory yields from LMM engineered cells.
2. Methods
2.1. Cloning and construction of vectors used for cell line engineering
A summary of the vectors generated in this study is outlined in the
associated Date in Brief (Budge et al., 2019) (Table 1). The process for
amplifying and cloning the CHO speciﬁc SCD1 gene sequence and the
SREBF1 mouse gene sequence is described in the associated Data in
Brief (Budge et al., 2019). The SREBF1 CHO cell gene sequence (NCBI
Fig. 1. Schematics illustrating the function of selected genes involved in lipid biosynthesis in eukaryotic cells. Figure A outlines the main regulatory
mechanisms of sterol regulatory element binding factor 1 (SREBF1). SREBF1 is initially expressed in the ER as a membrane integrated protein bound to the SCAP/
INSIG complex. In the presence of high sterol levels the aﬃnity level of INSIG is high and this complex is unable to migrate away from the ER (panel 1). In the absence
of sterols INSIG binds with low aﬃnity and can dissociate from the complex (panel 2). The SREBF1:SCAP complex can then migrate to the Golgi apparatus via
vesicles. Once in the Golgi S1P and S2P proteases sequentially cleave the SREBF1 molecule liberating the bHLH domain (panel 3) which can migrate into the nucleus
through the cytosol. The liberated SREBF1 molecule is subject to modiﬁcations such as ubiquitination and acetylation when in the cytosol which can activate or
repress degradation of the molecule respectively. When in the nucleus, nuclear SREBF1 (nSREBF1) is active as a transcriptional activator leading to the expression of
a plethora of genes involved in lipid metabolism. Figure B shows the role of stearoyl CoA desaturase 1 (SCD1); an enzyme involved in desaturation of saturated fatty
acids (SFA) to monounsaturated fatty acids (MUFA) which results in increased membrane ﬂuidity and lipid droplet formation. Furthermore, SCD1 can also directly
and indirectly inﬂuence the activity of acetyl CoA carboxylase (ACC) which is a rate limiting step involved in de novo lipogenesis. Overall, the activity of SCD1 can
increase the rate of lipid biosynthesis and enhance both cell survival and proliferation rates of the cell.
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accession no. NM_001244003.1) was synthesized by GeneART (Thermo
Fisher Scientiﬁc, USA) and cloned into a Lonza expression vector where
expression was driven by either what was considered to be a strong
(high, Fig. 5) or weaker (low, Fig. 5) promoter to drive transcription of
the SREBF1 CHO cell gene to relatively low or high levels. The vector
also encoded for a glutamine synthetase (GS) metabolic selection
marker to isolate cell pools.
Several vectors were constructed which contained the gene(s) for
appropriate expression of a range of diﬀerent format, industrially re-
levant biotherapeutics to be used as model molecules to assess the
performance of the engineering approach implemented and described
herein. An in-house Lonza expression vector containing sequences
based on chimeric B72.3 (cB72.3) antibody was used as a model IgG4
molecule (considered to be easy to express by the authors) and a second
Lonza vector was also utilized which contained sequences for appro-
priate expression of a model Fc-fusion protein (FcFP). An additional
vector for expression of a model IgG1 antibody (DTE-IgG1) which is
considered by the authors to be diﬃcult to express was also con-
structed. All vectors described above also contained the gene sequence
of glutamine synthetase (GS) for use as a metabolic selection marker
where necessary. Further detail can be found in the associated Data in
Brief (Budge et al., 2019).
2.2. Cell culture and cell line construction
The CHOK1SV GS-KO™ host cell line was cultured in CD-CHO
medium (ThermoFisher Scientiﬁc) supplemented with 6 mM L-gluta-
mine at 37 °C in a 5% CO2 environment and shaking at 140 rpm. Cells
were routinely counted using a ViCell (Beckman Coulter) instrument
using a 1 ml cell sample to determine viable and total cell concentra-
tions. Culture viability was estimated as the number of viable cells
expressed as a proportion of total cells. Cells were sub-cultured every
3–4 days, seeding new cultures at 0.2 × 106 viable cells per ml in 20 ml
of culture volume in a 125 ml Erlenmeyer ﬂask (Corning®). Following
cell line construction (see below) with vectors containing the GS gene,
cells were maintained in CD-CHO medium in the absence of L-gluta-
mine but in the presence of 25 μM L-methionine sulfoximine (MSX). In
order to generate and maintain cell pools and lines using vectors de-
rived from pcDNA3.1V5-His/TOPO, G418-disulphate (Melford, UK)
was supplemented into media to a ﬁnal concentration of 750 μg/ml.
The lipid metabolism modiﬁed CHOK1SV GS-KO™ cell pools CHO-
SCD1POOL, CHO-SREBF1POOL (mouse SREBF1 sequence) were generated
using linearized expression vectors whereas the CHO-ControlPOOL cells
were generated using the unmodiﬁed pcDNA3.1V5-His/TOPO vector.
The vectors used were linearized using PvuI restriction enzyme (NEB®).
The engineered pools were used to isolate clones via limiting one round
of dilutions and are considered to have a high probability of being
monoclonal (these clones are referred to as monoclonal lines herein).
LMM engineered cell pools and monoclonal lines were transfected with
a linearized GS containing vector (linearized with PvuI restriction en-
zyme (NEB®)) encoding either cB72.3 or the model FcFP. Producer
pools were selected for in glutamine-free medium supplemented to a
ﬁnal concentration of 25 μM MSX. In all cases, electroporation was
performed with 1 × 107 viable cells with 20 μg of each linearized
vector DNA in a BioRad cuvette using a GenePulser Xcell electroporator
(Bio-Rad). The DNA/cell mix was electroporated at 300 V and 900 μF in
a cuvette with a 0.4 cm electrode gap. Selection agent (either 25 μM
MSX or 750 μg/ml G418) was added 24 h post-transfection. Batch
cultures were initially seeded with 0.2 × 106 viable cells/ml in 20 ml
CD-CHO medium. Fed-batch cultures were also initially seeded at
0.2 × 106 viable cells/ml in 30 ml and eﬃcient feed B (ThermoFisher
Scientiﬁc) was supplemented at 0 h to comprise 15% of the total culture
volume. Further supplementation was carried out on day 3, 6 and 9 in
line with condition 3 as described in the manufacturer's instructions.
2.3. Western blotting
Western blotting was undertaken essentially as described previously
(Roobol et al., 2014). Details of primary and secondary antibody con-
jugates are outlined in Data in Brief (Budge et al., 2019) (Table 2).
2.4. Extraction of lipids from cells and subsequent mass spectrometry
analysis
Between 1.0 and 1.5 × 106 viable cells were pelleted by cen-
trifugation in a bench top centrifuge (Hereaus Biofuge pico for 5 min at
400 g), frozen immediately on dry ice and stored at−80 °C until lipids
were extracted. Each pellet was extracted by adding 3 ml of a 2:1
chloroform:methanol solution and 0.5 ml of water to the cell pellet.
This was then centrifuged in a bench top centrifuge (Thermo Megafuge
16R for 5 min at 3000 rpm, 1500 g at 4 °C) and then the lower
chloroform layer removed and dried under a nitrogen stream. Pellets
were resuspended in 150 μl of chloroform:methanol (2:1) and then
diluted 1:1 with a isopropanol:acetonitrile:water (2:1:1) solution.
Separation of the extracted lipids was performed on a Acquity UPLC
CSH C18 column (2.1 × 100 mm, 1.7 μm) using buﬀer A (acetoni-
trile:water (3:2) containing 10 mM ammonium formate and 0.1%
formic acid) and buﬀer B (isopropanol:acetonitrile (9:1) containing
10 mM ammonium formate and 0.1% formic acid v/v) and a ﬂow rate
of 0.4 ml/min. A gradient from 60% buﬀer A to 1% buﬀer A over
18 min was used for separation of lipids with the system being coupled
to the mass spectrometer. Mass spectrometry analysis of the material
eluting from the liquid chromatography system was performed on a
Synapt G2Si (Waters) mass spectrometer set to negative ionization
mode with MSE acquisition over 100 to 1200 m/z mass range with a
scan time of 0.5 s using a leucine encephalin LockSpray solution
(Waters) and the following instrument settings; collision energy
20–30 eV, capillary voltage 1.0 kV, cone voltage 40 V, desolvation
temperature 400 °C, desolvation gas 800 l/h and source temperature
100 °C. The data was analyzed using the Waters software UNIFI
searching a Waters Lipid Maps database. UNIFI was linked to EZInfo
software to generate the principal component analysis (PCA) plots.
2.5. Preparation of samples for immunoﬂuorescence analysis and capture of
images
In order to adhere suspension cells to coverslips, coverslips were
ﬁrst submerged in a poly-L-lysine solution (molecular weight
70,000–150,000 (P4707), Sigma Aldrich, USA) and incubated for
15 min at room temperature. Coverslips were then removed and left to
dry in a sterile environment before being transferred to a 24 well plate.
Cells were added to the wells at a concentration of 2 × 105 viable cells
per well and incubated in a static incubator for a minimum of 1 h before
further processing. Samples were ﬁxed and subsequently permeabilized
using 4% paraformaldehyde in PBS (w/v) followed by 0.1% Triton-
X100 in PBS (v/v) respectively. Samples were blocked using 3% BSA in
PBS (w/v) and exposed to the appropriate primary antibodies overnight
at 4 °C and secondary antibodies for 2 h at room temperature. The
details of the antibodies used are described in Data in Brief (Budge
et al., 2019) (Table 2). Finally, samples were exposed to DAPI (10 mg/
ml) before being mounting in ProLong™ Gold Antifade Mountant
(ThermoScientiﬁc). Images were captured using a Zeiss LSM 880/
Elyra/Axio Observer Z1 confocal microscope instrument.
2.6. Fluorescence microscopy image analysis for ER/Nuclear quantiﬁcation
Images for analysis were captured on a Zeiss LSM 880/Elyra/Axio
Observer Z1 confocal microscope as described above. Image analysis for
quantiﬁcation of ER size was performed using Zeiss Zen Blue software.
The “spline contour” tool was used to manually outline the outer
perimeter of the ER (highlighted using calnexin antibody Abcam
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ab22595) and the nucleus (highlighted by DNA staining with DAPI) and
the area of both were determined for each cell image. The outer area of
the ER deﬁnes both the ER and nuclear area and therefore the area
determined for the nucleus was subtracted from that of the area en-
closed by the ER to calculate the area of ER. The calculated ER area was
then divided by the area of nucleus to establish the ratio of ER area in
relation to the area of the nucleus through a cross section of each in-
dividual cell. Care was taken to ensure that the z-position of each of the
images ran approximately through the equator of the cells (determined
via the diameter of the nuclear stain). Since the estimated area of ER
may be dependent on the z-position, the nucleus was used to determine
the ratio to compensate for drift from the equator. Between 30-68 in-
dividual cells were analyzed per sample.
2.7. Electron microscopy analysis
Cells attached to poly-L-lysine coated Aclar membrane (Agar
Scientiﬁc) were ﬁxed for 2 h in 2.5% glutaraldehyde (w/v) in 100 mM
Fig. 2. Overexpression and cellular localization of SCD1 and SREBF1 in engineered cells. Western blot analysis of CHOK1SV GS-KO™ cells engineered to
overexpress either SCD1 or SREBF1 genes where controls have been generated with an unmodiﬁed pcDNA3.1V5-His/TOPO vector. CHO-Ctl-1, CHO-Ctl-2 and CHO-
Ctl-3 are monoclonal lines derived from the CHO-ControlPOOL; CHO-SCD1LOW, CHO-SCD1MID and CHO-SCD1HIGH are monoclonal cell lines isolated from CHO-
SCD1POOL and CHO-SREBF1LOW, CHO-SREBF1MID1 and CHO-SREBF1MID2 are monoclonal lines isolated from CHO-SREBF1POOL. The pools which had been engineered
were used to generate cells expressing cB72.3 (CHO-ControlcB72.3, CHO-SCD1cB72.3 and CHO-SREBF1cB72.3) or an Fc fusion protein (FcFP; CHO-ControlFcFP, CHO-
SCD1FcFP and CHO-SREBF1FcFP). Lysate samples were generated from these cells harvested at day 6 of culture from either host cells (A) or cells stably producing the
recombinant products cB72.3 or FcFP where speciﬁed (B). A primary antibody with speciﬁcity for L7α was used as a loading control. (C) Cellular localization of
overexpressed SCD1 and SREBF1 proteins in CHO-ControlPOOL, CHO-SCD1POOL and CHO-SREBF1POOL cell pools as determined by immunoﬂuorescent detection using
an anti-V5 antibody conjugated with a FITC secondary antibody. An anti-calnexin antibody conjugated with a TRITC secondary antibody was used to highlight the
position of the ER. Images were obtained using confocal microscopy (see Data in Brief (Budge et al., 2019) Table 2 for full details of antibodies used).
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sodium cacodylate (CAB) buﬀer pH 7.2. Samples were washed twice for
10 min in 100 mM CAB and then post-ﬁxed in 1% osmium tetroxide (w/
v) in 100 mM CAB for 1 h before being dehydrated using an ethanol
series of 50%, 70%, 90% (v/v) and 3 times with 100% ethanol for
10 min per step. The samples were then placed into propylene oxide, for
10 min, and following this into a 1:1 mixture of propylene oxide and
Agar LV resin (Agar Scientiﬁc) for 30 min. Following this, samples were
embedded in freshly prepared Agar LV resin twice for 2 h before being
placed in shallow aluminium moulds with the cells facing up and were
polymerized at 60 °C for 24 h before being examined with a dissecting
microscope to identify areas conﬂuent with cells. These areas were cut
out with a jig saw and attached to polymerized resin blocks with su-
perglue, and once attached, the Aclar membrane was peeled oﬀ, ex-
posing a monolayer of cells in the block face. Sections of 70 nm were
cut on a Leica EM UC7 ultramicrotome using a diamond knife
(Diatome) and were collected on 400 mesh copper grids. Sections were
counterstained in 4.5% uranyl acetate (w/v) in 1% acetic acid (v/v) for
45 min and in Reynolds’ lead citrate for 7 min. Samples were viewed in
a Jeol 1230 transmission electron microscope and images were cap-
tured with a Gatan One View 16mp camera.
2.8. Octet® measurement of recombinant protein concentrations
Recombinant molecule concentrations in cell culture supernatants
were determined using an Octet® instrument (ForteBio) with IgG cali-
brators and protein A biosensors. Product concentration and viable cell
concentrations determined using a ViCell instrument (Beckman
Coulter) were analyzed across at least three timepoints of culture to
calculate cell speciﬁc productivity values (Qp). Qp is equal to the gra-
dient of the line equation where the average product concentration was
plotted on the y axis and the average integral of viable cells (IVC) was
plotted on the x axis. IVC was calculated as shown in the equation
below where x is the viable cell number recorded at a timepoint, −x 1 is
the viable cell number recorded at the previous timepoint, t is the time
(in hours) that the timepoint was taken and −t 1 is the time (in hours) of
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2.9. Relative mRNA expression analysis by qRT-PCR
qRT-PCR was undertaken using Qiagen QuantiFast SYBR Green RT-
PCR kits essentially as previously described (Mead et al., 2015) using
FcFP speciﬁc primers. The amounts of the FcFP transcript was nor-
malized to that of the house keeping genes glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and β-actin as endogenous controls, and the
relative levels of expression of each sample calculated using the ΔΔCt
method.
3. Results
3.1. SCD1 and SREBF1 proteins can be overexpressed in CHO cells and
localize to the expected cellular location
To determine if manipulation of lipid metabolism in CHO cells could
be used to enhance cell growth and secretory recombinant protein ca-
pacity, we set out to engineer the expression of the transcription factor
SREBF1, and the desaturase SCD1. Respectively, these control the ex-
pression of multiple genes involved in lipid biosynthesis (SREBF1) and
the conversion of saturated fatty acids to monounsaturated fatty acids
(SCD1). We initially developed CHOK1SV GS-KO™ cell pools and clonal
cell lines engineered to overexpress each of these genes. In order to
develop stably expressing engineered cell pools, we initially used the
pcDNA3.1V5-His/TOPO vector (Thermo Fisher Scientiﬁc) which bears
a neomycin phosphate transferase selection marker (used with G418
sulfate (Melford) as the selection agent) to produce two vectors for
overexpression of either the CHO SCD1 or mouse SREBF1 genes under
the control of a CMV promoter and inclusive of a 3’ V5 tag. Polyclonal
cell pools which overexpress either SCD1 (CHO-SCD1POOL) or SREBF1
(CHO-SREBF1POOL) genes were generated using the pcDNA3.1V5-His/
TOPO derived vectors. A control cell pool was also generated using the
unmodiﬁed pcDNA3.1V5-His/TOPO vector and the resulting polyclonal
pool was named CHO-ControlPOOL. Clones which overexpressed the
LMM molecules were isolated from these original pools and western
blot analysis was undertaken on these clones, using antibodies speciﬁc
for SCD1 and SREBF1, in order to assess and rank relative amounts of
expression of the exogenous lipid modifying genes in the isolated clones
(data not shown). Three clones showing varying levels of LMM ex-
pression were selected from each pool for further analysis. No sig-
niﬁcant diﬀerence in SCD1 or SREBF1 protein amount was evident in
clones isolated from the CHO-ControlPOOL, as determined by western
blot, so the clones taken forward were selected at random.
Fig. 2A shows western blot analysis of the cell pools and isolated
clones to establish amounts of lipid metabolism modifying proteins
(SCD1 and SREBF1) with L7α being used as a loading control (Roobol
et al., 2009, 2014). The three clonal lines isolated from the CHO-Con-
trolPOOL were termed CHO-Ctl-1, CHO-Ctl-2 and CHO-Ctl-3. Isolated
clones from the CHO-SCD1POOL were named CHO-SCD1LOW, CHO-
SCD1MID and CHO-SCD1HIGH based on their relative SCD1 abundance as
conﬁrmed in the blots presented in Fig. 2A. Whilst endogenous levels of
SCD1 were not detectable in control or SREBF1 samples at the exposure
shown, all SCD1 overexpressing cells had elevated levels compared to
the control. Densitometry analysis (Data in Brief (Budge et al., 2019)
Fig. 1A) of the western blots showed that the low SCD1 (CHO-SCD1LOW)
clone had lower overexpression compared to that observed in the
polyclonal pool whilst the middle SCD1 overexpressing clone (CHO-
SCD1MID) levels were approximately 1.5-fold higher than that in the
CHO-SCD1POOL and the high clone (CHO-SCD1HIGH) had nearly a 7-fold
higher SCD1 expression (Data in Brief (Budge et al., 2019) Fig. 1A).
Both the pool and clones all had much higher SCD1 expression than the
controls.
Overexpression of SREBF1 was clearly evident in the polyclonal
pool (CHO-SREBF1POOL) engineered to overexpress the protein with
both the full length and nuclear SREBF1 (nSREBF1) levels higher than
observed in the controls (Fig. 2A and Data in Brief (Budge et al., 2019)
Fig. 1B). Both full length and nSREBF1 levels were determined for each
sample as only nSREBF1 is eﬀective as a transcriptional activator and
the engineering process reported here is dependent on the processing of
this molecule. Interestingly, when the SREBF1 polyclonal pool (CHO-
SREBF1POOL) was cloned, resulting clones did not have higher amounts
of SREBF1 expression than observed in the controls or the polyclonal
pool (CHO-SREBF1POOL). Nevertheless, a low (CHO-SREBF1LOW) and
two clones termed mid-SREBF1 expressers (CHO-SREBF1MID1 and CHO-
SREBF1MID2) were taken forward for further study.
The CHO-ControlPOOL, CHO-SCD1POOL and CHO-SREBF1POOL pools
were also transfected with expression vectors for either the model
chimeric IgG mAb cB72.3 or a model Fc Fusion Protein (FcFP). The
resulting pools were termed CHO-ControlcB72.3, CHO-SCD1cB72.3 and
CHO-SREBF1cB72.3 in those where the recombinant cB72.3 was stably
expressed and CHO-ControlFcFP, CHO-SCD1FcFP and CHO-SREBF1FcFP in
those where the model FcFP was stably expressed. Fig. 2B shows wes-
tern blot analysis of the resulting cell pools for SREBF1 (CHO-
SREBF1cB72.3 and CHO-SREBF1FcFP) and SCD1 (CHO-SCD1cB72.3 and
CHO-SCD1FcFP) expression. The SCD1 and SREBF1 proteins were
overexpressed in the appropriate lipid modiﬁed cells with high amounts
of SCD1 and SREBF1 expression observed compared to the control cells
(CHO-ControlcB72.3 and CHO-ControlFcFP). In the case of the SREBF1
overexpressing cells, both the full-length (SREBF1, band expected at
127 kDa) and nuclear SREBF1 (nSREBF1, band expected at 70 kDa)
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species were expressed at higher amounts than in the control cells in
both the CHO-SREBF1cB72.3 and CHO-SREBF1FcFP pools (Fig. 2B). The
presence of an aberrant, lower molecular weight SREBF1 band (42 kDa)
was observed in the CHO-SCD1cB72.3 and CHO-SREBF1cB72.3 pools
which was absent in the CHO-ControlcB72.3 and all the FcFP pool lysates
(Fig. 2B).
In addition to western blotting, immunoﬂuorescence analysis was
undertaken to conﬁrm overexpression of the target exogenous LMM
proteins and to determine the localization of the expressed exogenous
LMM proteins (Fig. 2C and Data in Brief (Budge et al., 2019) Fig. 1C).
An antibody against the V5 tag was used to detect the exogenous lipid
modifying proteins in the pools of engineered cells whilst an anti-cal-
nexin antibody, an established ER marker (Bergström et al., 2014;
Roobol et al., 2015), was used to deﬁne the ER and determine any co-
localization of the LMM proteins to the ER. The images shown in Fig. 2C
and the Data in Brief (Budge et al., 2019) Fig. 1C are representative of
all images obtained and conﬁrm exogenous SCD1 and SREBF1 protein
expression. Overlay of the V5 signal with the calnexin staining showed
co-localization suggesting that both proteins are localized to the ER,
consistent with previous literature reports (Sato et al., 1994; Man et al.,
2006). As described in the introduction, SREBF1 is initially localized to
the ER but translocated to the Golgi where it is processed by the cellular
machinery to liberate an N-terminal active transcription factor that is
able to migrate to the nucleus where it acts as a transcriptional
activator. However, since the V5 tag on the exogenous proteins was
present on the C-terminus of SREBF1, the mature N-terminal nuclear
species will not be detected using the V5 staining approach. The im-
munostaining of the full length SREBF1 protein yielded intense ﬂuor-
escent signal at the peri-nucleus, likely due to the presence of an
abundance of intracellular cholesterol which prevents migration of
SREBF1 subsequent to its initial localization, upon production, in the
ER (Rintoul et al., 1978).
3.2. CHO cells overexpressing the lipid metabolism modifying genes SCD1
and SREBF1 show diﬀerent batch culture growth proﬁles compared to
control host cells
We next determined if the overexpression of SCD1 or SREBF1 had
any impact on cell growth. Deﬁning the growth proﬁles was of parti-
cular interest since this attribute has been shown to be aﬀected by lipid
metabolism imbalances (Rintoul et al., 1978; McGrew et al., 1998).
Batch-cultures were setup in biological triplicate for each cell pool and
clonal cell line and samples taken daily to monitor the viable cell
concentration and culture viability (Data in Brief (Budge et al., 2019)
Fig. 2). There was no obvious impact on the growth characteristics of
exogenous SCD1 expression on CHO cell growth in the CHO-SCD1POOL
when compared to the CHO-ControlPOOL (Data in Brief (Budge et al.,
2019) Fig. 2A). However, clonal cells engineered to overexpress SCD1
Fig. 3. Productivity of model recombinant products in lipid engineered cell pools. cB72.3 and FcFP concentrations in supernatant of batch-cultured CHO-
ControlcB72.3, CHO-SCD1cB72.3 and CHO-SREBF1cB72.3 pools as well as CHO-ControlFcFP, CHO-SCD1FcFP and CHO-SREBF1FcFP pools. These cell pools were generated
by stably transfecting host pools engineered to overexpress SCD1 or SREBF1 proteins. The control was constructed using the original pcDNA3.1V5-His/TOPO vector.
cB72.3 (A) and FcFP (B) concentrations were measured using an Octet® from supernatants harvested at 48, 96, 144 and 192 h of culture. Speciﬁc productivity (C) was
calculated for cB72.3 (B) and FcFP (D) using these concentration values and corresponding cell growth measurements from the same time points. (D) shows the
relative amount of FcFP mRNA transcript in CHO-SCD1FcFP cells compared to CHO-ControlFcFP expressing cells from samples collected after 72 h of batch culture
relative to the two house keeping genes β-actin or GAPDH. n = 3 for each data point and error bars show ± one standard deviation.
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had diﬀerent growth proﬁles dependent on the relative SCD1 expres-
sion levels with CHO-SCD1LOW cells reaching the highest maximum
viable cell concentration of any culture (Data in Brief (Budge et al.,
2019) Fig. 2C). However, whilst the CHO-SCD1MID cells had a similar
growth proﬁle to the CHO-SCD1POOL, the CHO-SCD1HIGH cells initially
grew in a similar fashion but began to decline slowly in both viable cell
number and culture viability at an earlier timepoint (6 days, Data in
Brief (Budge et al., 2019) Fig. 2C). CHO-SCD1cB72.3 cells, expressing the
cB72.3 antibody, obtained a higher maximum viable cell concentration
compared to the CHO-ControlcB72.3 cultures at a later timepoint and
began to decline later than the control (Data in Brief (Budge et al.,
2019) Fig. 2E).
In comparison, the CHO-SREBF1POOL did not attain the same max-
imum viable cell concentration as the CHO-ControlPOOL or CHO-
SCD1POOL, suggesting that expression of endogenous SREBF1 negatively
impacted on the cells ability to attain higher viable cell concentrations
(Data in Brief (Budge et al., 2019) Fig. 2A). A similar pattern was ob-
served when the pools were engineered to express either cB72.3 (Data
in Brief (Budge et al., 2019) Fig. 2E) or the FcFP (Data in Brief (Budge
et al., 2019) Fig. 2F) molecules in SREBF1 overexpressing cell pools.
SREBF1 engineered overexpressing clones also showed variations in
growth proﬁles (Data in Brief (Budge et al., 2019) Fig. 2D). Whilst all
cells initially grew in a similar fashion, CHO-SREBF1MID2 cells obtained
the highest maximum viable cell concentration compared to other
SREBF1 engineered cells and the CHO-ControlPOOL. However, CHO-
SREBF1MID2 exhibited a decline in viable cell concentration from the
peak concentration to almost zero within 24 h between days 8 and 9 of
Fig. 4. Monoclonal antibody production in fed-batch conditions using
lipid engineered cells. cB72.3 concentrations in fed batch cultures where
supernatants were harvested from CHO-ControlcB72.3, CHO-SCD1cB72.3 and
CHO-SREBF1cB72.3 cultures at 144 and 216 h (6 and 9 days) of culture and feeds
were added on day 0, 3 and 6 where samples were harvested before feeding on
day 6. n = 3 for each data point and error bars show ± one standard devia-
tion.
Fig. 5. Analysis of SREBF1 engineered CHOK1SV GS-KO™ host cells stably expressing a variety of secretory recombinant biotherapeutic molecules. Cell
pools were constructed by the simultaneous co-transfection of two expression vectors. The ﬁrst vector contained the GS gene for selection as well as genes appropriate
for production of either cB72.3, FcFP or DTE-IgG1 whilst the second vector contained the SREBF1 gene driven by diﬀerent promoters to yield either low (SREBF1
Low) or high (SREBF1 High) SREBF1 protein abundance. Control pools (Control) were generated using the appropriate ﬁrst vector (also generated using GS selection)
in conjunction with an empty second vector (i.e. not encoding the SREBF1 gene). Western blot analysis was carried out to determine relative levels of SREBF1
abundance from cell pools constructed to express either cB72.3 (A), FcFP (B) or DTE-IgG1 (C) where SREBF1 Low, SREBF1 High or a Control vector were co-
transfected during the generation of pools as highlighted in the ﬁgure (L7a was used as a loading control). Figure D shows bands from a Coomassie blue stained SDS-
PAGE gel and densitometry analysis of bands corresponding to the recombinant products harvested at 7 days of batch culture from the constructed cell pools. All
lanes show bands corresponding to an independent cell pool construction.
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batch culture (Data in Brief (Budge et al., 2019) Fig. 2D). CHO-
SREBF1MID1 had a similar growth proﬁle to the control and CHO-
SREBF1LOW began to decline early in culture (6 days) than the other
SREBF1 engineered cells (Data in Brief (Budge et al., 2019) Fig. 2D).
3.3. CHO cells overexpressing SCD1 and SREBF1 have enhanced stable
secretory recombinant protein production capacity
A major aim of this study was to determine if engineering of lipid
metabolism in CHO cells impacted on secreted recombinant protein
concentration. We therefore next assessed whether stable engineering
of SCD1 or SREBF1 in the CHOK1SV GS-KO™ host cell line aﬀected the
concentration of secreted protein. Stable lipid engineered pools were
transfected to generate stably expressing secreted recombinant protein
pools using the stable CHO-ControlPOOL, CHO-SCD1POOL or CHO-
SREBF1POOL hosts and vectors containing the recombinant protein
cB72.3 or FcFP gene(s) with a GS selection marker. Culture supernatant
from the resulting pools were then analyzed using an Octet® instrument
to determine the proﬁles of cB72.3 or FcFP accumulation over 192 h (8
days) of batch culture (Fig. 3). Cells overexpressing SCD1 achieved
higher concentrations of both cB72.3 (Fig. 3A) and FcFP (Fig. 3B),
compared to the appropriate controls and across all timepoints mea-
sured. We also determined the relative transcript (mRNA) amounts of
the FcFP transcript normalized to the house keeping genes glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin in the
CHO-ControlFcFP and CHO-SCD1FcFP cell pools to conﬁrm that the ob-
served increase in FcFP secretory productivity was not brought about
by changes in mRNA amounts in the engineered cells compared to the
controls. As shown in Fig. 3D, the FcFP transcript amounts were not
elevated in CHO-SCD1FcFP expressing pools compared to the control
suggesting that the observed increased secretory amounts were not due
to changes at the transcript level.
Whilst the SCD1 engineered cells showed increased secretory re-
combinant protein productivity, cells overexpressing the mouse derived
SREBF1 gene did not produce higher cB72.3 concentrations than the
control and FcFP concentrations were lower (Fig. 3A and B). Speciﬁc
productivity in cells overexpressing SCD1 was increased approximately
4-fold for cB72.3 and 2.4-fold for FcFP (Fig. 3C) compared to the
controls under batch culture conditions. The CHO-SREBF1cB72.3 cell
speciﬁc productivity was similar to the CHO-ControlcB72.3 cells whilst
the CHO-SREBF1FcFP cell speciﬁc productivity was approximately half
of that of the CHO-ControlFcFP cells (Fig. 3C).
After assessing the performance of the LMM engineered CHO cell
pools for stable expression of the model recombinant proteins under
batch culture conditions, we investigated if fed-batch conditions af-
fected the observed increase in secreted protein yield. To assess this we
took samples at 144 and 216 h (day 6 and 9) during fed-batch culture of
the SCD1 and SREBF1 engineered cell pools that were stably expressing
the model mAb cB72.3 and determined the amount of secreted re-
combinant product in the cell culture supernatant. The resulting ana-
lysis showed that the CHOK1SV GS-KO™ pools engineered to over-
express SCD1 had a 9-fold and 5-fold increase in cB72.3 concentration
after 144 and 216 h (6 and 9 days) of fed-batch culture respectively
compared to the controls (Fig. 4). Pools engineered to overexpress
mouse SREBF1 showed a more modest increase in secreted product
concentration of approximately 1.5-fold above that of the control at
both timepoints (Fig. 4).
As described above, the CHO-SREBF1POOL engineered cell pools had
elevated amounts of SREBF1 protein expression compared to the con-
trols but the resulting SREBF1 engineered clonal lines did not have
elevated SREBF1 amounts compared to CHO-SREBF1POOL (see Fig. 2A
and Data in Brief (Budge et al., 2019) Fig. 1B). We therefore in-
vestigated if we could use the CHO speciﬁc SREBF1 gene sequence
under the control of promoters of diﬀerent strengths to generate en-
gineered cells with diﬀering intracellular levels of SREBF1, and then
make stable cell lines by co-transfection of the appropriate SREBF1
vectors with a second vector containing the GS selection marker and the
genes for the model product. To achieve this we used vectors with
promoters to drive either relatively high or low expression of SREBF1
and a second vector containing the genes for either of the mAb cB72.3
or DTE-IgG1 (a model IgG1 mAb considered by the authors to be dif-
ﬁcult to express), or the FcFP alongside the GS gene as the selectable
marker. Western blot analysis of SREBF1 expression in the resulting
pools conﬁrmed that varying levels (either high or low) were achieved
from the diﬀerent promoters utilized as intended. In the “high” SREBF1
pool there were elevated levels of both full length SREBF1 and nuclear
SREBF1 species in all pools (Fig. 5A–C). Coomassie blue staining of
model proteins on an SDS-PAGE revealed that the amount of product in
the supernatant in batch culture samples after 7 days of culture was 2-3-
fold higher in the high SREBF1 expressing pools compared to the con-
trol and low SREBF1 expressing pools (Fig. 5D). This suggests that the
amount of SREBF1 is integral to the success of the engineering approach
and that overexpression of the CHO speciﬁc SREBF1 gene sequence
improved recombinant titres to a greater degree than the mouse derived
gene. Collectively these data show that SCD1 and SREBF1 engineering
of CHO cell hosts can be used to generate hosts that yield enhanced
stable secretory recombinant product concentrations under batch and
fed-batch conditions, including standard monoclonal antibodies and
DTE un-natural molecules (e.g. those that do not exist in nature).
3.4. CHO cells overexpressing SCD1 and SREBF1 show enhanced transient
secretory recombinant protein production capacity
We also investigated whether the impact of stable overexpression of
SCD1 or SREBF1 in the CHOK1SV GS-KO™ host cell had an impact on
accumulation of model secreted recombinant proteins in a transient
expression system. To determine this, the engineered host pools (CHO-
ControlPOOL, CHO-SCD1POOL and CHO-SREBF1POOL) were transfected
with vectors containing the necessary genes for expression of a model
IgG mAb, cB72.3, or the diﬃcult to express FcFP and grown under
batch culture conditions with supernatant samples taken over a 96 h
period post-transfection for analysis of secreted product (Data in Brief
(Budge et al., 2019) Fig. 3). Both the CHO-SCD1POOL and CHO-
SREBF1POOL lipid modiﬁed cell pools produced increased concentra-
tions of both cB72.3 and the FcFP (Data in Brief (Budge et al., 2019)
Fig. 3A & C) compared to the control (CHO-ControlPOOL). By 96 h post-
transfection, both the CHO-SCD1POOL and CHO-SREBF1POOL cell pools
showed an approximate 60% increase in cB72.3 and 40% increase in
FcFP concentration compared to the CHOK1SV GS-KO™ control pool.
Western blot analysis was also undertaken on supernatant samples from
the cB72.3 and FcFP (Data in Brief (Budge et al., 2019) Fig. 3B & D)
transfected pools and showed more intense bands for the respective
products in the CHO-SCD1POOL and CHO-SREBF1POOL engineered pool
derived samples than from CHO-ControlPOOL.
Finally, we investigated whether the transient engineering of LMM
CHO cells could deliver enhanced transient product yields of a further
DTE secreted recombinant protein molecule. Being able to rapidly
produce higher yields of DTE molecules would facilitate rapid material
generation for early stage screening of such potential therapeutic mo-
lecules. For this purpose, a vector containing the three genes required
for expression of this further model DTE antibody fusion (IL2-F) and
either the SCD1 or SREBF1 gene (or no LMM gene in the control), were
transfected (on the same vector) by electroporation into the CHOK1SV
GS-KO™ host cell line. The Data in Brief (Budge et al., 2019) Fig. 4
shows analysis of supernatant samples harvested from transient batch
cultures at 96 h post-transfection with the aforementioned IL2-F vec-
tors. Octet® analysis of the supernatant samples showed that there was
an approximate 2.5-fold increase in transient IL2-F expression when
simultaneously expressed with the SCD1 gene compared to the control
whilst simultaneous expression with the SREBF1 gene produced 1.5-
fold more IL2-F compared to the control (Data in Brief (Budge et al.,
2019) Fig. 4). Western blot analysis of reduced supernatant samples
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conﬁrmed increased transient production of both the standard and
fused heavy chain molecules required for expression of IL2-F at 48 and
96 h post-transfection when SCD1 or SREBF1 were simultaneously ex-
pressed (Data in Brief (Budge et al., 2019) Fig. 4B).
3.5. CHO cells stably engineered to overexpress the lipid metabolism
modifying genes SCD1 and SREBF1 have altered lipid proﬁles and cellular
structure
Having shown that overexpression of the LMM proteins SCD1 and
SREBF1 could enhance secretory yields of various recombinant bio-
therapeutic proteins from CHO cells, we next set out to determine if this
resulted in changes to the lipid proﬁles/makeup of engineered cells and
their structure. We investigated this by mass spectrometry based lipid
proﬁling of whole cell lipid extracts from triplicate biological replicate
batch cultures harvested on day 6 of culture (with each sample ana-
lyzed in technical triplicate) and by electron microscopy of the en-
gineered pools and three clonal lines of the engineered and control
cells. Mass spectrometry data from the analysis of the lipids from
control and engineered cells were initially subjected to principal com-
ponent analysis (PCA) (Fig. 6A and B). These data show that the lipid
proﬁle of the CHO-SCD1HIGH clonal cell line clustered separately from
the other SCD1 engineered clones and polyclonal pool and from the
control samples (Fig. 6A). The CHO-SCD1MID cell line data points
tended to cluster between the CHO-SCD1HIGH and CHO-SCD1LOW cell
lines suggesting a link between SCD1 expression levels and the change
in the lipid proﬁle. PCA of the SREBF1 data showed that the CHO-
SREBF1LOW clone had a distinct lipid proﬁle from the other SREBF1
engineered clones, CHO-SREBF1POOL and the controls (Fig. 6B). CHO-
SREBF1MID1 and CHO-SREBF1MID2 clones clustered separately from
each other and the controls and CHO-SREBF1POOL engineered pools.
Collectively these data conﬁrm that there are changes to the global lipid
proﬁle of SCD1 and SREBF1 engineered cells compared to that in the
control cells.
We then analyzed individual lipid m/z mass peaks to identify spe-
ciﬁc lipids that changed in the SCD1 engineered cell lines and poly-
clonal pool compared to the control. We identiﬁed speciﬁc lipids that
were either upregulated (Data in Brief (Budge et al., 2019) Fig. 5A and
B) or downregulated (Data in Brief (Budge et al., 2019) Fig. 5D) in all
samples from the CHO-SCD1HIGH clone compared to the control and the
other SCD1 engineered clones and pool. This is consistent with the PCA
analysis of the total lipid proﬁles as determined by mass spectrometry
analysis whereby the CHO-SCD1HIGH clone was distinct from the others
and the protein analysis data (Fig. 2A and Data in Brief (Budge et al.,
2019) Fig. 1A), which showed that SCD1 expression was elevated in the
high clone to a much greater extent than in any of the other samples.
There were also many lipid ion peaks that were unchanged across all
samples (see Data in Brief (Budge et al., 2019) Fig. 5C for example).
Collectively, these data show that SCD1 and SREBF1 engineering of
CHO cells changes the lipid proﬁle of the cell and this is related to the
amount of overexpression of the individual LMM genes.
We also undertook electron microscopy analysis to determine if
changing the lipid proﬁle of CHO cells gave any observable diﬀerences
to the membrane and cellular structures in lipid modiﬁed cells (Fig. 7).
The images shown in Fig. 7 are representative of all images acquired for
each sample and are broadly separated into CHO-Control, CHO-SCD1
and CHO-SREBF1 cells where a single representative image for each of
the monoclonal or pool samples are displayed. The most striking dif-
ference between these samples was the diﬀerence in the plasma mem-
brane and cell morphology of SCD1 overexpressing cells. Whilst the
plasma membrane of all cells imaged exhibited protrusions, this feature
was particularly exaggerated in SCD1 overexpressing cells and Fig. 7C
shows images from CHO-SCD1POOL (Fig. 7Ci) and CHO-SCD1HIGH
(Fig. 7Cii, iii and iv) in which cells have an abundance of vesicle like
protrusions. This attribute was particularly common in CHO-SCD1HIGH
cells and is in alignment with an increased membrane ﬂuidity brought
Fig. 6. Analysis of cellular lipid content in control and LMM engineered CHO cells using mass spectrometry. (A) and (B) show Principal Component Analysis
(PCA) of the mass spectrometry derived lipid proﬁles extracted from cells overexpressing either SREBF1 or SCD1 genes highlighting diﬀerences in lipidomic proﬁles
of engineered CHOK1SV GS-KO cell lines harvested after 6 days of batch culture. Figure A shows PCA of control samples and samples engineered to overexpress
SCD1; black data points represent controls (CHO-Ctl-1 = ●, CHO-Ctl-2 = ▲, CHO-Ctl-3 = +, CHO-ControlPOOL = ■) whilst blue data points represent SCD1
overexpressing cells (CHO-SCD1LOW = , CHO-SCD1MID = +, CHO-SCD1HIGH = , CHO-SCD1POOL = ). Figure B shows analysis of control samples and samples
engineered to overexpress SREBF1; black data points represent controls (CHO-Ctl-1 = ●, CHO-Ctl-2 =▲, CHO-Ctl-3 = +, CHO-ControlPOOL =■) whilst red data
points represent SREBF1 overexpressing cells (CHO-SREBF1LOW = , CHO-SREBF1MID1 = , CHO-SREBF1MID2 = , CHO-SREBF1POOL = ). (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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about through the activity of SCD1. Additionally, a greater number of
membrane bound features such as vesicles were observed in SCD1 and
SREBF1 overexpressing cells in comparison to the relevant controls in
both host (Fig. 7A) and recombinant protein producing (Fig. 7B) cells.
3.6. Engineering of the lipid metabolism modifying genes SCD1 and SREBF1
in CHO cells results in an expansion of the ER
The ER is an organelle which requires high lipid turnover due to the
large abundance of continuous membrane required to contain it and is
also the major site of de novo lipogenesis. Induced ER expansion ap-
proaches have previously been successful in improving recombinant
protein productivity in CHO cells (Tigges and Fussenegger, 2006). In
consideration of this, ER area was estimated to determine if over-
expression of SCD1 and SREBF1 aﬀected ER size. ER size was quantiﬁed
on day 6 of batch culture relative to the nucleus, to ascertain whether
modifying cellular lipid content has an impact on ER expansion as de-
scribed in the methods section. Fig. 8 reports the data obtained from
this analysis and box and whisker plots show a wide range in the ratio
of ER to nucleus area in the control and engineered cells (Fig. 8A and
C). This can be explained by the general heterogeneity of each culture
analyzed. Attributes such as cell cycle stage and natural variation
within a population can account for the range of values attained but
clear patterns between diﬀerent cell lines were revealed through this
analysis.
The CHO-Ctl-1, CHO-Ctl-2, and CHO-ControlPOOL yielded similar
distributions in the ratio of ER:nucleus area whilst the latter showed a
greater range of values which is not unexpected in a polyclonal pool
compared to clonal cell lines (Fig. 8A). Conversely, CHO-Ctl-3 cells
showed lower ratios highlighting the variation that naturally arises
between diﬀerent clones but the range of each was within those ob-
served in the other controls. SCD1 modiﬁed cell lines showed diﬀer-
ences in ER size relative to the nucleus that was dependent on the re-
lative overexpression levels. CHO-SCD1LOW cells had the smallest
ER:nucleus ratio values, CHO-SCD1MID show values similar to the CHO-
ControlPOOL and CHO-SCD1HIGH cells showed increased ER:nuclear area
values. Thus, the high expressing SCD1 clone had an increased ER area
compared to the nucleus indicative of a general expansion of the ER on
average in the cells in this clone. Alternatively, lower overexpression of
SREBF1 had higher ER:nuclear area ratios; CHO-SREBF1LOW cells had
increased ER:nuclear area in comparison to controls whilst CHO-
SREBF1MID1 and CHO-SREBF1MID2 cells show sequentially decreasing
average values (Fig. 8A and B). Interestingly, the CHO-SREBF1POOL had
the highest ER:nuclear area ratio overall. Whilst box and whisker plots
show the entire range of values obtained, mean values calculated from
these data are also presented within the box blot and individually
Fig. 7. Images obtained by electron microscopy of cells engineered to overexpress lipid modifying genes. Samples were taken at day 6 of batch culture and
observed using a Jeol 1230 transmission electron microscope and images were captured using a Gatan One View 16mp camera. Monoclonal and host cell pools (A)
and cB72.3 and FcFP expressing cells (B) were imaged and representative images are shown for all cells included in this study. Figure (C) shows images from CHO-
SCD1POOL (i) and CHO-SCD1HIGH (ii, iii and iv) of membrane protrusions observed frequently in these cells.
J.D. Budge, et al. Metabolic Engineering 57 (2020) 203–216
213
(Fig. 8B).
When this analysis was undertaken on the engineered cell pools
stably expressing secretory recombinant proteins, the ER:nuclear ratio
was generally lower than the corresponding non-producing counter-
parts. However, the trend observed across these was similar to the hosts
alone whereby the CHO-SCD1cB72.3 pools had a small increase in ER
compared to the CHO-ControlcB72.3 pools, whilst the CHO-SREBF1cB72.3
pool had an approximate 40% increase in ER area on average (Fig. 8C
and D). Interestingly, analysis of FcFP expressing cells shows that CHO-
SCD1FcFP cells also had a small increase in ER area compared to the
CHO-ControlFcFP but that the CHO-SREBF1FcFP cells did not appear to
show any indication of ER expansion compared to the control (Fig. 8C
and D).
4. Discussion
The data presented here report the ﬁrst studies to directly modify
lipid metabolism in CHO cells by engineering the overexpression of
proteins involved in lipid biosynthesis. CHO cells are the established
workhorse for the synthesis of biotherapeutic proteins and decades of
process development have been successfully implemented to enhance
the capacity of existing CHO hosts for production of a variety of re-
combinant molecules, but particularly mAbs (Walsh, 2018). Previous
cellular engineering strategies have focused on cell metabolism, cell
cycle control, protein secretion/chaperone manipulation, apoptosis and
post-translational modiﬁcation of recombinant proteins (Yiping et al.,
2010). However, as lipids are essential in many of the processes that
underpin secretory recombinant protein production from mammalian
cell systems, it is somewhat surprising that there have been few eﬀorts
to understand and manipulate lipid biogenesis in CHO cells with a view
to enhancing their ability to produce such proteins. We therefore hy-
pothesized that the manipulation of lipid metabolism pathways could
bring about desired attributes for biotherapeutic production in CHO
cells.
SREBF1 was overexpressed in CHO cells with the aim to increase the
overall rate of lipid turnover and modify existing lipid species by
transcriptionally activating a plethora of genes involved in lipid meta-
bolism. The functionality and survival of eukaryotic cells is reliant on
tightly regulated lipid homeostasis and the accumulation of excessive
lipids can induce lipotoxicity leading to apoptosis (Kliewer et al., 1997;
van Herpen and Schrauwen-Hinderling, 2008). It is likely that a large
increase in de novo lipogenesis promoted by high SREBF1
Fig. 8. Quantiﬁcation of ER area in relation to nuclear area calculated using immunoﬂuorescence confocal microscopy. ER and nuclear features which were
highlighted using an anti-calnexin antibody (an established ER marker (Roobol et al., 2009)) followed by conjugation with a TRITC secondary antibody and DAPI
respectively and images were taken at the approximate equator of the cell on the z axis, as determined by the intensity and diameter of the DAPI stain. Values
obtained were measured using the “spline contour” tool of Zen blue software to outline the ER and nuclear features of the cells. All cells were adhered and ﬁxed to
coverslips on day 6 of batch culture and all images analyzed were from this timepoint. A & B show values from pools and monoclonal host CHO cells engineered to
overexpress SCD1 or SREBF1 and control CHO cells, generated using the original pcDNA3.1V5-His/TOPO vector whilst C & D show cells stably expressing either
cB72.3 or the FcFP generated from control, SCD1 or SREBF1 host pools. Further, A & C show box and whisker plots generated from values obtained where all
individual recorded data points are represented by dots and B & D show mean values obtained using these data points (n≥ 30). (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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overexpression could have a detrimental eﬀect on CHO host survival.
This theory is supported by the fact that only a modest increase in
SREBF1 is observed in engineered cells, suggesting that high expressing
cells were unable to survive in the recovered population. Furthermore,
stable expression of SREBF1 at higher levels appeared to have an ad-
verse eﬀect on cell growth in culture. This was the case for both host
and cB72.3 or FcFP producing cells, which did not grow to the same
viable cell concentration as the relevant controls. However, clonal hosts
overexpressing SREBF1 to lower levels than the polyclonal pool (which
expressed the highest amount) showed less dramatic changes in growth
proﬁles. The CHO-SREBF1MID2 cell line obtained a higher maximum
viable cell number but perished more quickly than other SREBF1 en-
gineered cell pools and lines.
The data presented in this study suggest that there is an ‘optimal’
level of SREBF1 in CHO host lines to achieve desired attributes and that
tuning of SREBF1 expression to diﬀerent extents could either improve
or negatively impact on growth and productivity characteristics of CHO
cells. Lower levels of SREBF1 overexpression also showed the greatest
increase in ER size of the monoclonal CHO-SREBF1 cells whilst higher
expression levels showed progressively lower average ER size compared
to the nucleus. Interestingly, CHO-SREBF1POOL cells showed the
greatest increase in ER size overall suggesting that overexpression of
SREBF1 can induce ER expansion, perhaps since its expression is en-
dogenously upregulated in the UPR and contributes to the tuning of the
abundance of lipids required for ER expansion (Han and Kaufman,
2016; Basseri and Austin, 2012). Interestingly, cells that show increased
ER size also show compromised growth proﬁles, which may be a result
of either cell stress or a limit in resources and energy availability.
ER size was considerably lower in CHO cells expressing recombinant
products than in non-expressing counterparts. This is likely due to
diﬀerences in growth proﬁles, brought about by the introduction of the
recombinant molecules, where impacts on cell cycle progression can
considerably aﬀect organelle morphology (van Meer et al., 2008;
English and Voeltz, 2013; Heald and Cohen-Fix, 2014). Interestingly,
cells producing the IgG4 molecule cB72.3 showed a similar trend, in
terms of ER size, to their host counterparts i.e. SREBF1 overexpressing
cells show an increased ER area compared to the control for both the
host pool and producing cell pools. Conversely, CHO-SREBF1FcFP cells
had ER sizes more similar to the relevant control. It has previously been
demonstrated that bottlenecks in secretory recombinant protein pro-
duct yields are dependent on both the molecule and cell line used for
expression (Mayrhofer et al., 2015; Mason et al., 2012). Whilst SREBF1
overexpression was able to transiently boost cB72.3, FcFP and antibody
fusion expression (Budge et al., 2019), it did not initially exhibit the
same eﬀect in a stable scenario where the increases in cB72.3 produced
were more modest. However, when higher expressing stable SREBF1
pools were generated by co-transfection of the CHO cell speciﬁc SREBF1
with three diﬀerent recombinant molecules the higher expressing
SREBF1 pools had a 2-3-fold increase in the stable expression of the
secreted recombinant molecules (Fig. 5), providing further evidence
that the amount of SREBF1 overexpression is important in ‘dialing in’
the desired eﬀect on CHO cell phenotype. It is also noteworthy that
stable overexpression of the CHO speciﬁc SREBF1 gene sequence gen-
erated higher titres of model recombinant molecules than when the
mouse derived gene was employed suggesting that the speciﬁc SREBF1
sequence may be important in the success of this engineering approach.
Overexpression of SCD1 increased secretory recombinant yields of all
molecules evaluated and was shown to be eﬀective in both transient
and stable scenarios. This shows that SCD1 is able to modify CHO cells
such that cellular processes involved in recombinant protein production
are enhanced.
A combination of membrane lipid composition, the presence of
membrane integral proteins, cellular scaﬀolds and cytoskeletal as-
sembly can inﬂuence mechanisms of membrane curvature during ve-
sicle budding processes (McMahon and Gallop, 2005). It has been
suggested that a decrease in membrane rigidity can lower the energy
required for vesicle formation (Settles et al., 2010). Since SCD1 in-
creases membrane ﬂuidity through the conversion of SFA to MUFA, it is
likely that overexpression of SCD1 increases the propensity for vesicle
formation. This is supported by the data presented in Fig. 7 where CHO-
SCD1 cells showed higher numbers of vesicles on the surface, and in
some cases intracellularly, of engineered cells. Furthermore, the in-
hibition of SCD1 in huh7 cells has been shown to decrease the size of
lipid droplets (Ben M'barek et al., 2017). Conversely, large vesicles were
frequently observed when SCD1 was overexpressed in CHO cells in the
current study. Elongated protrusions at the plasma membrane were also
observed in SCD1 overexpressing cells likely due to an increase in
membrane ﬂuidity. Whilst the implications this may have on re-
combinant protein production is unknown, this phenomenon is likely to
increase the surface area to volume ratio increasing the contact surface
that these hosts have with external medium and increasing the potential
for secretion via fusion of cell membranes. An increase in vesicle bud-
ding and traﬃcking may increase the secretory capacity of the CHO
hosts and the SCD1 engineered cells consistently had improved re-
combinant concentrations. In addition, an increase in lipid droplet
formation or size may increase energy storage and lipid availability and
this process has been shown to protect cells against lipotoxicity in CHO
cells (Plötz et al., 2016).
In conclusion, we show for the ﬁrst time that cellular engineering of
lipid metabolism can be employed to enhance desired attributes and
cellular processes, increasing both transient and stable secretory bio-
therapeutic production from cultured CHO cells. Excitingly, this study
provides proof-of-concept of an entirely new approach to engineer CHO
cells for enhanced bioprocessing attributes that may allow further en-
hancement of existing and new CHO expression systems to generate
hosts that allow improved production of a range of more easy and DTE
proteins. Importantly, we have also shown that engineering of these
targets in other host CHO cells delivers a similar impact on product
yields to that observed in the host described here (data not shown).
However, in order to obtain the maximum enhanced attributes from
CHO cells engineered to overexpress either SCD1, involved in formation
of MUFAs, or SREBF1, involved in more global control of lipid bio-
genesis, it will be necessary to tune the amount of expression of these
LMM genes in engineered CHO cells. As such, development and com-
mercialization of new lipid engineered host cell lines will require the
generation of stably expressing cell lines with speciﬁc SCD1 or SREBF1
proﬁles that may diﬀer depending on the target secretory molecule to
be expressed. Finally, the success of this approach highlights the im-
portance of lipids in mammalian cell culture processes for the produc-
tion of secreted biopharmaceuticals in general and provides further
evidence that lipidomics should be applied to the understanding and
enhancement of expression systems in the bioprocessing industry as
suggested by others (Zhang et al., 2017).
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